公开(公告)号：US20220177858A1

公开(公告)日：2022-06-09

申请号：US17604722

申请日：2020-04-17

Applicant: Genomatica, Inc.

Inventor： Michael A. Noble ,  Russell Scott Komor ,  Jingyi Li

IPC: C12N9/10 ,  C12N15/52 ,  C12N1/20 ,  C12P7/22

Abstract: Described herein are non-natural olivetol synthase (OLS) variants, nucleic acids, engineered cells, method s for preparing cannabinoids, and compositions thereof. The non-natural olivetol OLS variants form desired cannabinoid precursor and products at increased rates, have higher affinity for pathway substrates, and/or byproducts are formed in lower amounts in their presence, as compared to wild type OLS. The OLS variants can be used to form linear polyketides, and can be expressed in an engineered cell having a pathway to form cannabinoids, which include CBGA, its analogs and derivatives. CBGA can be used for the preparation of cannabigerol (CBG), which can be used in therapeutic compositions.

公开(公告)号：US20220348890A1

公开(公告)日：2022-11-03

申请号：US17605499

申请日：2020-04-24

Applicant: Genomatica, Inc.

Inventor： Amit M. Shah ,  Harish Nagarajan ,  Joseph Roy Warner ,  Russell Scott Komor

IPC: C12N9/10 ,  C12P13/00

Abstract: Disclosed are transaminase (TA) enzymes and nucleic acids encoding them. In some cases, the transaminase enzymes are non-natural, engineered transaminases. Also disclosed are biosynthetic methods and engineered microorganisms that enhance or improve the biosynthesis of 6-aminocaproate, hexamethylenediamine, caproic acid, caprolactone, or caprolactam. The engineered microorganisms include exogenous TA and in some cases engineered TA.

公开(公告)号：US20220315969A1

公开(公告)日：2022-10-06

申请号：US17616842

申请日：2020-06-05

Applicant: Genomatica Inc.

Inventor： Michael Angus Noble ,  Russell Scott Komor

IPC: C12P17/06 ,  C12N1/20 ,  C12N15/70 ,  C12N15/52 ,  C12P7/42

Abstract: Described herein are olivetolic acid cyclases (OAC) including non-natural variants capable of forming a 2,4-dihydroxy-6-alkylbenzoic acid from a 3,5,7-trioxoacyl-CoA or a 3,5,7-trioxocarboxylate substrate. In some examples, the non-natural OAC is capable of forming a 2,4-dihydroxy-6-alkylbenzoic acid from a 3,5,7-trioxoacyl-CoA or a 3,5,7-trioxocarboxylate substrate at a greater rate. In some examples, the non-natural OAC has a higher affinity for a 3,5,7-trioxoacyl-CoA or a 3,5,7-trioxocarboxylate substrate, as compared to the wild type OAC. The non-natural OAC can be used with olivetol synthase (OLS) to form the 2,4-dihydroxy-6-alkylbenzoic acid from malonyl-CoA and acyl-CoA through to a 3,5,7-trioxoacyl-CoAintermediate. The non-natural OAC (and OLS) can be expressed in an engineered cell having a pathway to form cannabinoids, which include CBGA, its analogs and derivatives. CBGA can be used for the preparation of cannabigerol (CBG), which can be used in therapeutic compositions.